Literature DB >> 16034094

CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions.

Valerie Dardalhon1, Anna S Schubart, Jayagopala Reddy, Jennifer Hartt Meyers, Laurent Monney, Catherine A Sabatos, Rakesh Ahuja, Khuong Nguyen, Gordon J Freeman, Edward A Greenfield, Raymond A Sobel, Vijay K Kuchroo.   

Abstract

Surface molecules that are differentially expressed on Th1 and Th2 cells may be useful in regulating specific immune responses in vivo. Using a panel of mAbs, we have identified murine CD226 as specifically expressed on the surface of differentiated Th1 cells but not Th2 or Th0 cells. Although CD226 is constitutively expressed on CD8 cells, it is up-regulated on CD4 cells upon activation. Th1 differentiation results in enhanced CD226 expression, whereas expression is down-regulated upon Th2 polarization. We demonstrate that CD226 is involved in the regulation of T cell activation; in vivo treatment with anti-CD226 results in significant reduction of Th1 cell expansion and in the induction of APCs that inhibit T cell activation. Furthermore, anti-CD226 treatment delays the onset and reduces the severity of a Th1-mediated autoimmune disease, experimental autoimmune encephalomyelitis. Our data suggest that CD226 is a costimulatory molecule that plays an important role in activation and effector functions of Th1 cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16034094     DOI: 10.4049/jimmunol.175.3.1558

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

1.  Intranodal interaction with dendritic cells dynamically regulates surface expression of the co-stimulatory receptor CD226 protein on murine T cells.

Authors:  Sebastian Seth; Quan Qiu; Simon Danisch; Michael K Maier; Asolina Braun; Inga Ravens; Niklas Czeloth; Rebecca Hyde; Oliver Dittrich-Breiholz; Reinhold Förster; Günter Bernhardt
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

2.  NKG2D is required for NK cell activation and function in response to E1-deleted adenovirus.

Authors:  Jiangao Zhu; Xiaopei Huang; Yiping Yang
Journal:  J Immunol       Date:  2010-11-12       Impact factor: 5.422

3.  Non-synonymous variant (Gly307Ser) in CD226 is associated with susceptibility to multiple autoimmune diseases.

Authors:  Amit K Maiti; Xana Kim-Howard; Parvathi Viswanathan; Laura Guillén; Xiaoxia Qian; Adriana Rojas-Villarraga; Celi Sun; Carlos Cañas; Gabriel J Tobón; Koichi Matsuda; Nan Shen; Alejandra C Cherñavsky; Juan-Manuel Anaya; Swapan K Nath
Journal:  Rheumatology (Oxford)       Date:  2010-03-24       Impact factor: 7.580

4.  The CD226 gene in susceptibility of rheumatoid arthritis in the Chinese Han population.

Authors:  Yan Du; Ling-Xun Shen; Li-Kai Yu; You Song; Jian-Fang Zhu; Rong Du
Journal:  Rheumatol Int       Date:  2011-02-01       Impact factor: 2.631

Review 5.  From markers to molecular mechanisms: type 1 diabetes in the post-GWAS era.

Authors:  Alan G Baxter; Margaret A Jordan
Journal:  Rev Diabet Stud       Date:  2012-12-28

Review 6.  A novel interface consisting of homologous immunoglobulin superfamily members with multiple functions.

Authors:  Zhuwei Xu; Boquan Jin
Journal:  Cell Mol Immunol       Date:  2010-01       Impact factor: 11.530

Review 7.  [T-cell costimulation. Basic mechanisms and new aspects].

Authors:  A Hutloff
Journal:  Z Rheumatol       Date:  2011-09       Impact factor: 1.372

Review 8.  Tim-3, Lag-3, and TIGIT.

Authors:  Nicole Joller; Vijay K Kuchroo
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

Review 9.  Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.

Authors:  Ana C Anderson; Nicole Joller; Vijay K Kuchroo
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

10.  The expanding genetic overlap between multiple sclerosis and type I diabetes.

Authors: 
Journal:  Genes Immun       Date:  2008-11-06       Impact factor: 2.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.